These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25291078)

  • 1. Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib.
    Niwa N; Nishiyama T; Ozu C; Yagi Y; Saito S
    Acta Oncol; 2015 Apr; 54(4):561-2. PubMed ID: 25291078
    [No Abstract]   [Full Text] [Related]  

  • 2. Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
    Takada M; Yasui T; Oka T; Shioyama W; Kuroda T; Nakai Y; Nishimura K; Mukai M; Fujita M
    Int Heart J; 2018 Sep; 59(5):1174-1179. PubMed ID: 30158382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
    Edeline J; Laguerre B; Rolland Y; Patard JJ
    Ann Oncol; 2010 Jan; 21(1):186-7. PubMed ID: 19875754
    [No Abstract]   [Full Text] [Related]  

  • 4. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
    Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases].
    Soto M; Campanario R; Saiz R; Juárez A
    Arch Esp Urol; 2016 Sep; 69(7):440-3. PubMed ID: 27617555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axitinib controlled metastatic renal cell carcinoma for 5 years.
    Takayama T; Nagata M; Kai F; Sugiyama T; Ozono S
    Jpn J Clin Oncol; 2013 Jul; 43(7):747-51. PubMed ID: 23667154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axitinib-induced acute pancreatitis: a case report.
    Péron J; Khenifer S; Potier V; Vitry T; Pasquet F; Rassat R; Pavic M
    Anticancer Drugs; 2014 Apr; 25(4):478-9. PubMed ID: 24398664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
    Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E
    Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
    De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
    J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential Sunitinib-Induced Coronary Artery and Aortic Dissections.
    Hatem R; Bebawi E; Schampaert E
    Can J Cardiol; 2017 Jun; 33(6):830.e17-830.e18. PubMed ID: 28461000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
    Huang J; Wang T; Huang Y
    Med Oncol; 2013 Mar; 30(1):436. PubMed ID: 23283650
    [No Abstract]   [Full Text] [Related]  

  • 13. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dysthyroidism with anti-VEGF treatment, a class effect? about one case report].
    Khouri C; Jean Bart E; Logerot S; Decker-Bellaton A; Bontemps H; Mallaret M
    Therapie; 2014; 69(6):521-4. PubMed ID: 25293486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

  • 16. Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
    Qin S; Zhang S
    Chin Clin Oncol; 2015 Mar; 4(1):15. PubMed ID: 25841722
    [No Abstract]   [Full Text] [Related]  

  • 17. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
    Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
    Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Axitinib in metastatic renal carcinomas: update of knowledge about side effects].
    Albiges L; Izzedine H; Ederhy S; Robert C; Gravis G; Boyle H; Scotté F; Hartl D; Escudier B
    Bull Cancer; 2014 Oct; 101(10):976-88. PubMed ID: 25373697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
    Abdel-Rahman O; Fouad M
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):194-207. PubMed ID: 25028151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib.
    Miyake H; Harada K; Imai S; Miyazaki A; Fujisawa M
    Int J Clin Oncol; 2015 Aug; 20(4):796-801. PubMed ID: 25424248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.